PHSI-BRG
PHSI-BRG
Home
Staff
Sarah Al Ashmori
Andy Bryant
Thomas Chadwick
Mike Cole
Trinh Dong
Chioma Elewa
Holly Fisher
Tony Fouweather
Sophie Greenwood
Dorcas Kareithi
Ann Breeze Konkoth
Nan Lin
Ellen Moss
Helen Mossop
Aritra Mukherjee
Ayon Mukherjee
Jérémie Nsengimana
Marzieh Shahmandi
Konstantin Shestopaloff
Moha Shojaei
David Sinclair
Elaine Stamp
James Wason
Nina Wilson
Yingjuan Zhang
PhD students
Nicole Cizauskas
Emily Clements
Niamh Fitzgerald
Raiann Hamshaw
Prika Huang
Ben Keane
Sofiia Kravchenko
Laura Morgan
Methodology research
Overview
Adaptive designs
Master protocols
Transforming IMID trials
Projects
Publications
News
Courses
Adaptive Designs and Multiple Testing Procedures
Leveraging External Information
Precision Medicine Clinical Trials
Contact
Light
Dark
Automatic
Lozano-Kuehne
Somatostatin Receptor Imaging with [18F]FET-βAG-TOCA PET/CT and [68Ga]Ga-DOTA-Peptide PET/CT in Patients with Neuroendocrine Tumors: A Prospective, Phase 2 Comparative Study
[$łess$sup$greater$18$łess$/sup$greater$F]Fluorothymidine(FLT)-PET imaging of thymidine kinase 1 pharmacodynamics in non-small cell lung cancer treated with pemetrexed.
Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer
The HERPET study: Imaging HER2 expression in breast cancer with the novel PET tracer [$łess$sup$greater$18$łess$/sup$greater$F]GE-226, a first-in-patient study.
Predictors for single-agent resistance in FIGO score 5 or 6 gestational trophoblastic neoplasia: a multicentre, retrospective, cohort study
Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy
[18F]Fluciclatide PET as a biomarker of response to combination therapy of pazopanib and paclitaxel in platinum-resistant/refractory ovarian cancer
Altered cytochrome 2E1 and 3A P450-dependent drug metabolism in advanced ovarian cancer correlates to tumour-associated inflammation
[$łess$sup$greater$18$łess$/sup$greater$F] Fluciclatide PET as a biomarker of clinical response to combination therapy of pazopanib and paclitaxel in patients with platinum-resistant or platinum-refractory advanced ovarian cancer: Results of a phase Ib study.
Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study~of~Heart~and Renal Protection (SHARP)
»
Cite
×